journal article·2024-06-09Open access

Effects of Functional Biomaterials on the Attributes of Orally Disintegrating Tablets Loaded with Furosemide Nanoparticles: In Vitro and In Vivo Evaluations

Doaa Alshora, Wejdan Alyousef, Mohamed Ibrahim

Abstract

Furosemide (FUR) is a diuretic used to relieve edema, congestive heart failure, cirrhosis, end-stage renal disease, and hypertension. FUR is a class IV according to the Biopharmaceutics Classification System. It is practically insoluble in water. This study aimed to optimize and formulate porous orally disintegrating tablets (ODTs) prepared by sublimation and loaded with FUR nanoparticles prepared by using a planetary ball mill. Different functional biomaterials called stabilizers were used to stabilize the nanoparticle formula. Pluronic F-127 was the optimum stabilizer in terms of particle size (354.07 ± 6.44), zeta potential (−25.3 ± 5.65), and dissolution efficiency (56.34%). The impact of the stabilizer concentration was studied as well, and a concentration of 3% showed the smallest particle size (354.07 ± 6.44), best zeta potential value (−25.3 ± 5.65), and percentage of dissolution rate (56.34%). A FUR-loaded nanoparticle formula was successfully prepared. The nanoparticle formula was stabilized by using 3% pluronic F-127, and 3% was chosen for further study of the incorporation into oral disintegration tablets prepared by the sublimation technique. The impact of the matrix sublimating agent and superdisintegrant on the ODTs’ attributes (in vitro disintegration, wetting time, and in vitro dissolution efficiency) was studied using 32 full factorial designs. In vivo, the diuretic activity was tested for the optimized FUR ODTs by calculating the Lipschitz value using rats as an animal model. The stability of the ODTs loaded with FUR nanoparticles was assessed under accelerated conditions for 6 months. Finally, the ODT formula loaded with FUR NPs showed a rapid onset of action that was significantly faster than untreated drugs. Nanonization and ODT formulation enhances the dissolution rate and bioavailability of FUR. Many factors can be controlled to achieve optimization results, including the formulation and process parameters.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Drug Solubulity and Delivery Systems · Pharmacological Effects and Toxicity Studies · Epilepsy research and treatment

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 22452, Riyadh 11459, Saudi Arabia

Funding

King Saud University, Riyadh, Saudi Arabia

References (37)

Show source-provided references
1. Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association10.1002/ejhf.2115 ↗
2. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the prevention, detection, and management of heart failure in Australia 201810.1016/j.hlc.2018.06.1042 ↗
3. The use of diuretics in heart failure with congestion—A position statement from the Heart Failure Association of the European Society of Cardiology10.1002/ejhf.1369 ↗
4. Diuretic therapy for patients with heart failure: JACC Stateof-the-Art Review10.1016/j.jacc.2019.12.059 ↗
5. Data base of aqueous solubility for organic non-electrolytes
6. Nanotechnology from particle size reduction to enhancing aqueous solubility
7. Application of liquisolid technology for enhancing solubility and dissolution of rosuvastatin
8. Alshora, D.H., Ibrahim, M.A., Elzayat, E., Almeanazel, O.T., and Alanazi, F. (2018). Rosuvastatin calcium nanoparticles: Improving bioavailability by formulation and stabilization codesign. PLoS ONE, 13.10.1371/journal.pone.0200218 ↗
9. Defining the process parameters affecting the fabrication of rosuvastatin calcium nanoparticles by planetary ball mill10.2147/IJN.S207301 ↗
10. Co-stabilization of pioglitazone HCL nanoparticles prepared by planetary ball milling: In-vitro and in-vivo evaluation10.1080/10837450.2020.1744163 ↗
11. Conceptual stabilizer selection for nanomilling based on dispersibility parameters10.1016/j.apt.2023.104197 ↗
12. Orally disintegrating tablets—Advantages and drawbacks
13. Fast Dissolving Tablet by Sublimation Technique: A Review
14. The concept of dissolution efficiency10.1111/j.2042-7158.1975.tb09378.x ↗
15. Factorial design, formulation, in vitro and in vivo evaluation of rapid orally disintegrating tablets prepared by sublimation technique using captopril as a model drug
16. The United States Pharmacopeial Convention (2011). 〈905〉 Uniformity of Dosage Units, The United States Pharmacopeial Convention.
17. In vitro and in vivo evaluation of nimesulide lyophilized orally disintegrating tablets10.1016/j.ejpb.2009.04.005 ↗
18. Wen, X., Deng, Z., Xu, Y., Yan, G., Deng, X., Wu, L., Liang, Q., Fang, F., Feng, X., and Yu, M. (2021). Preparation and In Vitro/In Vivo Evaluation of Orally Disintegrating/Modified-Release Praziquantel Tablets. Pharmaceutics, 13.10.3390/pharmaceutics13101567 ↗
19. Bioassay of diuretics
20. Stability of nanosuspensions in drug delivery10.1016/j.jconrel.2013.08.006 ↗
21. Nanosuspensions of poorly soluble drugs: Preparation and development by wet milling10.1016/j.ijpharm.2011.03.050 ↗
22. Tuomela, A., Hirvonen, J., and Peltonen, L. (2016). Stabilizing Agents for Drug Nanocrystals: Effect on Bioavailability. Pharmaceutics, 8.10.3390/pharmaceutics8020016 ↗
23. Nanosuspensions a promising formulation for the new phospholipase A2 inhibitor PX-1810.1016/j.ijpharm.2010.03.002 ↗
24. Clarithromycin dissolution enhancement by preparation of aqueous nanosuspensions using sonoprecipitation technique
25. Effect of concentration and molecular weight of polyethylenimine on zeta potential, isoelectric point of nanocrystalline silicon carbide in aqueous and ethanol medium10.1016/j.ceramint.2014.11.115 ↗
26. Improvement of Domperidone Solubility and Dissolution Rate by Dispersion in Various Hydrophilic Carriers10.7324/JAPS.2016.60720 ↗
27. Furosemide (fusemide): A pharmacokinetic/pharmacodynamic review. Part I
28. Characterization of the complexes of furosemide with 2-hydroxypropyl-bcyclodextrin and sulfobutylether-7-b-cyclodextrin10.1016/S0928-0987(02)00107-0 ↗
29. Optimized furosemide taste masked orally disintegrating tablets
30. Synthesis and Characterization of Furosemide Complex in ß-Cyclodextrain
31. Physicochemical characterization and dissolution study of solid dispersions of furosemide with polyethylene glycol 6000 and polyvinylpyrrolidone K3010.14227/DT150308P17 ↗
32. Formulation and Pharmacokinetics of Flurbiprofen Sublimated Fast Dissolving Tablets10.2174/1874844901502010056 ↗
33. Thio, D.R., Heng, P.W., and Chan, L.W. (2022). MUPS Tableting-Comparison between Crospovidone and Microcrystalline Cellulose Core Pellets. Pharmaceutics, 14.10.3390/pharmaceutics14122812 ↗
34. Physicochemical interactions between drugs and superdisintegrants10.1211/jpp.60.12.0003 ↗
35. Formulation and evaluation of orally disintegrating clopidogrel tablets10.1590/S1984-82502016000200009 ↗
36. Lee, T.H., Kuo, G., and Chang, C.H. (2021). Diuretic effect of co-administration of furosemide and albumin in comparison to furosemide therapy alone: An updated systematic review and meta-analysis. PLoS ONE, 16.10.1371/journal.pone.0260312 ↗
37. Time of onset of vardenafil orodispersible tablet in a real-life setting—Looking beyond randomized clinical trials